Articles tagged with Prostate Cancer
Prostate cancer cells rewire amino acid metabolism to override normal brakes on cholesterol production, fueling hormone therapy resistance. Restricting isoleucine and valine in the diet may slow tumor growth and improve treatment response, while boosting propionyl-CoA levels promotes tumor growth.
A national study found that about half of prostate cancer patients receiving focal therapy fell outside the recommended patient groups, highlighting the need for evidence-based treatment decisions. The study emphasizes the importance of understanding which patients are most likely to benefit from promising new treatments.
A randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer found that stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT for disease-free survival at 3 years. However, SBRT showed better bowel-related quality of life compared to IMRT.
Active surveillance for favorable-risk prostate cancer increased significantly in the Veterans Affairs healthcare system, with high rates among low-risk and intermediate-risk patients. This trend suggests that many veterans are avoiding unnecessary treatment, but disparities in care persist.
This retrospective study examines patterns and trends of focal therapy for nonmetastatic prostate cancer in US cancer centers. Focal therapy procedures remained uncommon, occurring mostly in low-, high-, or very-high-risk disease settings.
A retrospective cohort study of 16,924 men found metabolic syndrome and related abnormalities during the first year of treatment. Hypertension was the most common metabolic outcome among patients receiving concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor.
A new study found that the majority of veterans with low-risk prostate cancer pursued active surveillance in 2024, up from 27% in 2005. The study followed over 73,000 veterans and showed similar survival outcomes for surveillance compared to treatment.
A new study from Florida Atlantic University finds that men who consume high amounts of ultra-processed foods have increased risks of prostate cancer. Men with the highest UPF intake had a possible 34% higher risk, although the finding did not reach statistical significance.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A new study uses spatial transcriptomics to map the molecular evolution of prostate cancer and identifies key genes associated with disease progression. The research reveals that genetic malignancy in specific glandular epithelial regions tightly aligns with increasing clinical Gleason scores.
A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is associated with improved patient survival, and this cutoff may be the best metric for determining treatment success, according to investigators analyzing Veterans Health Administration data.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
A phase 3 clinical trial led by Weill Cornell Medicine shows that adding a targeted radionuclide therapy drug to backbone therapy reduces disease progression in patients with PSMA-positive metastatic prostate cancer. The treatment may delay symptom progression and improve patient outcomes.
A new study uses mathematical biomarkers to accurately predict prostate cancer patient outcomes and survival, outperforming traditional PSA monitoring. These metrics can inform personalized treatment protocols, enabling more effective adaptive therapy.
A team of researchers at UMass Amherst has developed an AI model, DiffuDose, that generates a patient's radiation dose map with gold-standard accuracy in under 23 seconds. This technology has the potential to unlock the full potential of radiopharmaceutical therapy for prostate cancer treatment.
Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...
A Rice University research team created prostate cancer cells that can survive high-force moments in the body, a process known as mechanoresistance. The study found that a gene called CALB2 plays a key role in this ability, with increased expression linked to metastatic cancer.
Researchers used advanced 3D genome mapping technology to study prostate cancer cells and discovered a new feature of gene control networks that could help fight cancer. The study found that enhancers work cooperatively in 3D networks, with some acting as central hubs that control many genes.
A recent cohort study found similar rates of secondary treatment receipt among men with localized prostate cancer by race, but observed mortality disparities persisted. These findings raise concerns about healthcare inequities and the need for targeted interventions to address racial disparities in cancer care.
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer most likely to benefit from <sup> 223 </sup> Ra radiopharmaceutical therapy and monitor their progress. The test showed associations between ctDNA profiles and clinical outcomes, including biomarker response and overall survival.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
The study creates a radiohybrid approach that labels a single molecule with two different diagnostic radionuclides, enabling long-term visualization of therapeutic agent distribution. This allows for personalized cancer medicine by calculating optimal radiation doses for individual patients.
A new study identifies a rare genetic mutation in the CDK12 gene as a cause of aggressive prostate cancer at a young age. Genetic testing for this mutation could help identify families at risk and support early cancer detection, potentially saving lives.
A second PSMA PET scan changed treatment plans for nearly half of patients whose first scan was negative, detecting evidence of disease in 56% of cases. The study found that repeat imaging was most likely to detect disease in patients with higher PSA levels and a PSA doubling time of less than twelve months.
Researchers at the University of Texas MD Anderson Cancer Center have identified genetic factors that determine whether prostate cancers are susceptible to ferroptosis. SPOP mutations and CHD1 deletions could serve as biomarkers to help identify patients who may benefit from emerging ferroptosis-based therapies.
Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A new blood test, Stockholm3, detected significantly more aggressive prostate cancers than the PSA test without increasing unnecessary follow-ups. The study shows that Stockholm3 identifies 90% of aggressive cancer cases, compared to 74% for PSA.
A new study found that conversations about prostate cancer screening are uncommon in primary care visits but lead to higher screening rates when they do occur. The study suggests a gap between national guidelines and clinical practice, highlighting the importance of shared decision-making for individualized care.
A hospital-based study in India found that higher coffee consumption and meat intake were associated with lower odds of prostate cancer. The researchers identified potential biological mechanisms behind these findings, but note that the relationship between diet and prostate cancer is complex and warrants further investigation.
Prostate cancer cells use the PIM1 protein to survive treatment by activating autophagy, a cellular recycling process. Researchers have discovered a potential strategy to overcome this resistance by removing the PIM1 protein entirely using a proteolysis-targeting chimera.
A new division at the James Buchanan Brady Urological Institute will support research, education, and care for urological conditions. The gift will accelerate advancements in surgical training, imaging, and technology to improve patient outcomes.
Researchers at UT MD Anderson Cancer Center have made significant advances in understanding cancer biology, developing AI-powered atlas of tertiary lymphoid structures as prognostic biomarkers, and uncovering drivers of resistance to KRAS inhibitors. Additionally, they have discovered a molecular pathway that drives stressed cells to b...
A recent study analyzing 670,000 patients found a higher frequency of advanced disease among non-white men and differences in access to modern therapies. The study also revealed significant racial inequalities in treatment costs, with white patients receiving 16.2% more funding.
A phase 3 clinical trial found that apalutamide plus hormone therapy before and after surgery reduced the risk of metastasis or death by 20% compared to hormone therapy alone. Patients treated with this regimen had a higher pathologic response rate and experienced delayed subsequent therapy.
Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.
A new poll by Physicians Committee for Responsible Medicine finds that most men consider a carnivore diet to be 'masculine' and would change their diet if it put their health at risk. The survey also found that consuming meat is linked to an increased risk of heart disease, erectile dysfunction, and reduced fertility.
Researchers discovered that androgen receptor signaling acts as a transcriptional repressor of liver receptor homolog-1 (LRH-1) in prostate cancer. This finding reveals a previously unknown mechanism of gene regulation and highlights the potential for targeting this axis to manage advanced prostate cancer.
Research finds ceramide metabolism differences between Black and white individuals with metastatic castration-resistant prostate cancer influence treatment outcomes. Genetic ancestry-related variants affect ceramide levels and ratios, which promote cell survival or death.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
Dropping the cancer label from grade group (GG)1 prostate disease redefines it as a precancerous lesion, leading to a net reduction in estimated prostate cancer deaths. This relabeling strategy may have minimal impact on screening rates.
Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
A study published by the European Society for Radiotherapy and Oncology found that delivering radiotherapy in just two sessions over eight days is safe and effective for treating prostate cancer. The treatment had no additional side effects compared to the standard five doses, making it a convenient option for patients.
A Phase 2 trial found that combining opaganib with abiraterone and enzalutamide showed promising results in slowing disease progression and improving patient outcomes. The treatment's tolerability was also well-tolerated, with most side effects mild to moderate.
Researchers at the University of Texas MD Anderson Cancer Center have identified a new marker, FOXA1, which shows high sensitivity in diagnosing small cell carcinoma of the prostate. This breakthrough offers hope for improving patient care and prognostic decisions.
Kondapa Naidu Bobba, a nuclear engineering professor, has been awarded the PCF-SNMMI Young Investigator Award to advance prostate cancer research. The award will support his research on radiopharmaceutical therapies to improve treatment outcomes for patients with metastatic castration-resistant prostate cancer.
Screening with a PSA blood test reduces prostate cancer deaths by approximately 2 for every 1,000 men screened. The review found that 500 men would need to be invited to screening to prevent one prostate cancer death.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
A randomized clinical trial found that testosterone treatment significantly improved sexual activity, sexual desire, and quality of life scores in men after prostate cancer surgery. The treatment also improved body composition and aerobic performance without increasing the risk of biochemical recurrence.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
A new urine test, MPS2-AS, performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active surveillance. The test correctly predicted high-grade cancer in 97% of cases and avoided unnecessary biopsies by up to 64%.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
A new study found that prostate cancer overdiagnosis increases with age, with low rates in younger men and high rates in older men. The study suggests that targeted PSA testing or screening policies for men in their 50s and early 60s may be more effective.
New research suggests that federal housing assistance may lead to better two-year survival chances among older men with prostate cancer. The study found a 12% lower risk of death in men who received housing assistance compared to those without it.
Research finds PDX1 gene plays a tumor-promoting role in human PCa cells by influencing metabolic pathways. The study identifies PDX1 as differentially hypermethylated in prostate cancer tissues, contributing to its aggressive characteristics.